Data from a phase 2 study suggests that use of E6011, a new human anti-fractalkine monoclonal antibody, may be beneficial for rheumatoid arthritis (RA) patients with an inadequate response to methotrexate. E6011 led to significant clinical improvements, especially in those with higher CD16+ monocytes. In addition to its efficacy, E6011 was overall well-tolerated in Japanese RA patients naïve to methotrexate.
Fractalkine (CX3CL1) is a chemokine that regulates chemotaxis and cell adhesion of leukocytes expressing the cognate receptor, CX3CR1, during their migration. The serum level of fractalkine is elevated in patients with RA and is linked to disease activity. Peripheral blood CD16+ monocytes and a subset of T cells express CX3CR1, while fractalkine is expressed on fibroblast-like synoviocytes and endothelial cells in the synovial tissue of patients with RA .
Dr Yoshiya Tanaka et al. (University of Occupational and Environmental Health, Japan) ev...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Preliminary Efficacy and Safety Data of RG6125 in RA Patients with an Inadequate Response to TNF Inhibitors Next Article
Tapering of Prednisone in RA Patients Who Achieved Low Disease Activity or Remission with Tocilizumab »
Table of Contents: EULAR 2019
Osteoarthritis and Osteoporosis
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.